- Home
- CRVS vs GRPN Comparison
CRVS vs GRPN Comparison
Compare CRVS & GRPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- GRPN
- Stock Information
- Founded
- CRVS 2014
- GRPN 2008
- Country
- CRVS United States
- GRPN United States
- Employees
- CRVS N/A
- GRPN N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- GRPN Advertising
- Sector
- CRVS Health Care
- GRPN Consumer Discretionary
- Exchange
- CRVS Nasdaq
- GRPN Nasdaq
- Market Cap
- CRVS 516.0M
- GRPN 473.0M
- IPO Year
- CRVS 2016
- GRPN 2011
- Fundamental
- Price
- CRVS $4.99
- GRPN $10.40
- Analyst Decision
- CRVS Buy
- GRPN Hold
- Analyst Count
- CRVS 4
- GRPN 3
- Target Price
- CRVS $12.83
- GRPN $17.00
- AVG Volume (30 Days)
- CRVS 1.6M
- GRPN 1.6M
- Earning Date
- CRVS 11-12-2024
- GRPN 11-12-2024
- Dividend Yield
- CRVS N/A
- GRPN N/A
- EPS Growth
- CRVS N/A
- GRPN N/A
- EPS
- CRVS N/A
- GRPN 0.52
- Revenue
- CRVS N/A
- GRPN $499,894,000.00
- Revenue This Year
- CRVS N/A
- GRPN N/A
- Revenue Next Year
- CRVS N/A
- GRPN $0.32
- P/E Ratio
- CRVS N/A
- GRPN $20.03
- Revenue Growth
- CRVS N/A
- GRPN N/A
- 52 Week Low
- CRVS $1.30
- GRPN $7.75
- 52 Week High
- CRVS $10.00
- GRPN $19.56
- Technical
- Relative Strength Index (RSI)
- CRVS 28.00
- GRPN 46.52
- Support Level
- CRVS $3.77
- GRPN $11.20
- Resistance Level
- CRVS $7.44
- GRPN $11.74
- Average True Range (ATR)
- CRVS 0.60
- GRPN 0.96
- MACD
- CRVS -0.41
- GRPN -0.12
- Stochastic Oscillator
- CRVS 25.85
- GRPN 29.72
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About GRPN Groupon Inc.
Groupon Inc acts as the middleman between consumers and merchants, offering a variety of products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.